5-HT3 Antagonists (Antiemetics) and Cardiac Safety
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
5-HT3 antagonists (ondansetron) are highly effective medications for the treatment of nausea
and vomiting. However, these medications also associated with potentially severe and
life-threatening cardiac adverse drug reactions (ADRs), particularly QT prolongation. Data
regarding the cardiac safety and inter-individual variability in cardiac effects of
ondansetron when used in vulnerable populations such as children and pregnant women are very
limited. The results of this study will enable better-informed therapeutic decision-making
regarding the use of ondansetron in children and pregnant women, with the overall goal to
improve the safety of these commonly used antiemetic medications. Furthermore, predictive
pharmacogenetic markers of severe 5-HT3 antagonist toxicity could be used to identify
patients at risk of cardiac toxicity before the drug is administered.